Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 136-144

  Kanda, Mitsuro ^a   Shimizu, Dai ^a   Nomoto, Shuji ^a   Hibino, Soki ^a   Oya, Hisaharu ^a   Takami, Hideki ^a   Kobayashi, Daisuke ^a   Yamada, Suguru ^a   Inokawa, Yoshikuni ^a   Tanaka, Chie ^a   Fujii, Tsutomu ^a   Sugimoto, Hiroyuki ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

expression; gastric cancer; intragenic methylation; tumor suppressor; TUSC1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; GENOMIC DNA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE LOCUS; GENE MAPPING; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERITONEUM LAVAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STOMACH CANCER; STOMACH CARCINOGENESIS; SURVIVAL RATE; TUMOR BLEEDING; TUMOR INVASION; TUMOR LOCALIZATION; TUMOR SUPPRESSOR CANDIDATE 1 GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

EXPRESSION; GASTRIC CANCER; INTRAGENIC METHYLATION; TUMOR SUPPRESSOR; TUSC1;

ADULT; AGED, 80 AND OVER; CELL LINE, TUMOR; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; EPIGENETIC REPRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84904065389     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23614     Document Type: Article

References (45)

1. Siegel R, Ward E, Brawley O, et al.: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Herrera V, Parsonnet J,: Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009; 15: 971-976.
3. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. González C, Agudo A,: Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go. Int. J Cancer 2012; 130: 745-753.
5. Vogiatzi P, Vindigni C, Roviello F, et al.: Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 2007; 211: 287-295. (Pubitemid 46580082)
6. Bae JM, Lee EJ, Guyatt G,: Citrus fruit intake and stomach cancer risk: A quantitative systematic review. Gastric Cancer 2008; 11: 23-32. (Pubitemid 351464480)
7. Larsson SC, Orsini N, Wolk A,: Processed meat consumption and stomach cancer risk: A meta-analysis. J Natl Cancer Inst 2006; 98: 1078-1087. (Pubitemid 44288156)
8. Tramacere I, Negri E, Pelucchi C, et al.: A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 2012; 23: 28-36.
9. Shikata K, Doi Y, Yonemoto K, et al.: Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: The Hisayama study. Am J Epidemiol 2008; 12: 1409-1415.
10. El-Omar M, Carrington M, Chow M, et al.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402. (Pubitemid 30164342)
11. Fukuda K, Saikawa Y, Ohashi M, et al.: Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 2009; 34: 1201-1207.
12. Petrocca F, Visone R, Onelli M, et al.: E2F1-regulated microRNAs impair TGF-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008; 13: 272-286. (Pubitemid 351318375)
13. The Study Group of Millennium Genome Project for Cancer: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 2008; 40: 730-740.
14. Ueda T, Volinia S, Okumura H, et al.: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
15. Park WS, Oh RR, Park JY, et al.: Frequent somatic mutations of the β-catenin gene in intestinal-type gastric cancer. Cancer Res 1999; 59: 4257-4260. (Pubitemid 29418739)
16. Toyota M, Ahuja N, Suzuki H, et al.: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-5442. (Pubitemid 29526452)
17. Etoh T, Kanai Y, Ushijima S, et al.: Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004; 164: 689-699. (Pubitemid 38364682)
18. Kanda M, Nomoto S, Okamura Y, et al.: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcino 2011; 50: 571-579.
19. Issa JP,: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-993.
20. Jang BG, Kim WH,: Molecular pathology of gastric carcinoma. Pathobiology 2011; 78: 302-310.
21. Kanda M, Nomoto S, Oya H, et al.: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol 2014; 44: 44-52.
22. Lee JH, Park SJ, Abraham SC, et al.: Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 2004; 23: 4646-4654. (Pubitemid 38850413)
23. Tomita H, Takaishi S, Menheniott TR, et al.: Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppressor of TFF1 epigenetic silencing. Gastroenterology 2011; 140: 879-891.
24. Ueno M, Toyota M, Akino K, et al.: Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 2004; 25: 134-140. (Pubitemid 39274282)
25. Yin M, Hu Z, Tan D, et al.: Molecular epidemiology of genetic susceptibility to gastric cancer: Focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res 2009; 1: 44-54.
26. Kanda M, Nomoto S, Okamura Y, et al.: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol 2009; 35: 477-483.
27. Shan Z, Parker T, Wiest JS,: Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. Oncogene 2004; 23: 6612-6620. (Pubitemid 39265524)
28. Yang XR, Liang X, Pfeiffer RM, et al.: Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer 2010; 9: 625-633.
29. Shan Z, Shakoori A, Bodaghi S, et al.: TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. PLoS ONE 2013; 8: e66114.
30. Takami H, Kanda M, Oya H, et al.: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol 2013; 108: 557-562.
31. Sobin LH, Gospodarowicz MK, Wittekind C,: International Union Against Cancer. TNM classification of malignant tumors, 7th edition. New York: Wiley-Blackwell; 2009.
32. Shah MA, Khanin R, Tang L, et al.: Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 2011; 17: 2693-2701.
33. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. (Pubitemid 350044801)
34. Kanda M, Nomoto S, Nishikawa Y, et al.: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 2008; 98: 190-196.
35. Nomoto S, Kanda M, Okamura Y, et al.: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010; 17: 923-932.
36. Takai D, Jones PA,: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002; 99: 3740-3745. (Pubitemid 34252176)
37. Takai D, Jones PA,: The CpG island searcher: A new WWW resource. In Silico Biol 2003; 3: 235-240. (Pubitemid 37493047)
38. Maunakea AK, Nagarajan RP, Bilenky M, et al.: Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466: 253-257.
39. Ball M, Li JB, Gao Y, et al.: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27: 361-368.
40. Weber M, Davies JJ, Wittig D, et al.: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37: 853-862. (Pubitemid 41077111)
41. Flanagan J, Wild L,: An epigenetic role for noncoding RNAs and intragenic DNA methylation. Genome Biol 2007; 8: 307.
42. Lorincz M, Dickerson D, Schmitt M, et al.: Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol 2004; 11: 1068-1075. (Pubitemid 39453335)
43. Jones PA,: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
44. Pollock P, Welch J, Hayward N,: Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res 2001; 61: 1154-1161. (Pubitemid 32174438)
45. Kim NG, Kim JJ, Ahn JY, et al.: Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer 2000; 85: 633-638. (Pubitemid 30080474)